Filing Details

Accession Number:
0001181431-13-032856
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-06-05 16:01:48
Reporting Period:
2013-06-05
Filing Date:
2013-06-05
Accepted Time:
2013-06-05 16:01:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1571498 Epizyme Inc. EPZM Pharmaceutical Preparations (2834) 261349956
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
318154 Amgen Inc
One Amgen Center Drive
Thousand Oaks CA 91320-1799
No No Yes No
1576997 Amgen Ventures Llc One Amgen Center Drive
Thousand Oaks CA 91320-1799
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-06-05 317,460 $0.00 317,460 No 4 C Direct
Common Stock Acquisiton 2013-06-05 16,666 $15.00 334,126 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2013-06-05 952,381 $0.00 317,460 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
Footnotes
  1. Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.
  2. These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
  3. Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock.